Retension Pharmaceuticals, Inc. (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 3,750,000 shares of common stock at $12 per share. The offering is expected to generate gross proceeds of $45 million before underwriting discounts, commissions, and other offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 562,500 shares to cover over-allotments, if any. Shares were expected to begin trading on the Nasdaq Capital Market on October 9, 2026, under the ticker symbol RTSN, with the offering scheduled to close on or about October 13, subject to customary closing conditions. The substantial capital injection arrives at a pivotal time for Retension as it seeks to advance its lead clinical candidate, RTN-001, through mid- and late-stage development.
The proceeds from the IPO are earmarked to complete the company's ongoing Phase 2b clinical trial of RTN-001 for uncontrolled hypertension and to prepare for, support, and advance a planned Phase 3 trial. Remaining funds will be allocated to general corporate purposes and operating expenses. This financial milestone is significant because it provides the resources necessary to generate the clinical data required for regulatory submission and potential commercialization. Uncontrolled hypertension remains a major global health challenge, affecting millions of patients who do not achieve target blood pressure despite available therapies. A successful Phase 2b readout and subsequent Phase 3 trial could position RTN-001 as a novel treatment option for this underserved population.
Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are serving as joint bookrunning managers for the offering, with Titan Partners acting as lead manager. The involvement of these reputable investment banks underscores institutional confidence in Retension's pipeline and strategic direction. For investors, the IPO offers an opportunity to participate in a clinical-stage biopharmaceutical company with a focused cardiovascular portfolio. The company's progress can be tracked through market research platforms such as Retension (NASDAQ: RTSN), which provide ongoing updates on its stock performance and corporate developments.
Retension Pharmaceuticals is dedicated to developing medicines for hypertension and other cardiovascular diseases. Its lead candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension. For more details about the company's pipeline and mission, visit https://www.retensionpharmaceuticals.com/. The full press release announcing the IPO pricing is available at https://ibn.fm/uko0m.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on wire-grade press release syndication for private and public companies. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. This broad reach ensures that news like Retension's IPO pricing reaches a wide audience of investors, influencers, and the general public, maximizing visibility and brand awareness for the company.
